Uremic Pruritus - Pipeline Insight, 2024

This “Uremic Pruritus - Pipeline Insight, 2024” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Uremic Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Uremic Pruritus: Understanding

Uremic Pruritus: Overview

Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus (CKD-aP), is a common and distressing condition affecting patients with advanced chronic kidney disease (CKD), especially those on dialysis. It manifests as persistent itching, typically without a clear dermatological cause, and can significantly reduce the quality of life. The exact mechanisms are not fully understood but are thought to involve systemic inflammation, metabolic imbalances, and the buildup of uremic toxins due to impaired kidney function.

The primary symptom of uremic pruritus is persistent, intense itching, which can occur across the body or be localized to areas like the back, face, or arms. The itching is often worse at night, disrupting sleep and leading to fatigue and reduced quality of life. Unlike other skin conditions, there are typically no visible skin changes initially, but chronic scratching can lead to secondary lesions, redness, and thickening of the skin. Uremic pruritus is often accompanied by symptoms of chronic kidney disease, such as dry skin, muscle cramps, and general discomfort, further complicating the patient's condition.

The diagnosis of uremic pruritus is primarily clinical, based on a patient's history of chronic kidney disease (CKD) and the presence of persistent itching without an identifiable dermatological cause. Physicians typically rule out other causes of pruritus, such as allergies, liver disease, or dermatological conditions, through physical exams, blood tests, and skin assessments. In patients with CKD, the diagnosis is often supported by symptoms like generalized or localized itching, particularly if it worsens at night. The treatment of uremic pruritus focuses on symptom management and improving quality of life, as there is no definitive cure. Treatment approaches include optimizing dialysis to reduce the buildup of uremic toxins and addressing metabolic imbalances, such as hyperparathyroidism. Topical therapies like emollients and moisturizers are used to alleviate dry skin, while antihistamines and gabapentinoids may help reduce itching. Systemic treatments, such as opioid receptor modulators (e.g., nalfurafine) and immunomodulatory drugs like corticosteroids, can also provide relief. Phototherapy, particularly narrowband ultraviolet B (UVB) therapy, has been shown to be effective for some patients.

"Uremic Pruritus - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uremic Pruritus pipeline landscape is provided which includes the disease overview and Uremic Pruritus treatment guidelines. The assessment part of the report embraces, in depth Uremic Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uremic Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Uremic Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Uremic Pruritus.

Uremic Pruritus Emerging Drugs Chapters

This segment of the Uremic Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uremic Pruritus Emerging Drugs

QLG2198: Qilu Pharmaceutical

QLG2198 is a therapeutic drug currently under development by Qilu Pharmaceutical, primarily aimed at treating pruritus (itching). The clinical development of QLG2198 is ongoing in China, indicating that it is still in the testing phases to assess its efficacy and safety for potential use in patients. The specific mechanism of action for QLG2198 is currently unknown. Currently, the drug is in the Phase III stage of its development for the treatment of Uremic Pruritus.

Uremic Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Uremic Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Uremic Pruritus

There are approx. 2+ key companies which are developing the therapies for Uremic Pruritus. The companies which have their Uremic Pruritus drug candidates in the most advanced stage, i.e. Phase III include, Qilu Pharmaceutical.

Phases

The report covers around 2+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uremic Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uremic Pruritus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uremic Pruritus drugs.

Uremic Pruritus Report Insights

• Uremic Pruritus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uremic Pruritus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uremic Pruritus drugs?
• How many Uremic Pruritus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uremic Pruritus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uremic Pruritus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uremic Pruritus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Qilu Pharmaceutical

Key Products

• QLG2198

This product will be delivered within 2 business days.